Takeda Pharmaceuticals Valuation Multiples

Takeda Pharmaceuticals Overview

About Takeda Pharmaceuticals

Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Founded

1925

HQ

Employees

49.3K

Website

takeda.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $29B

EBITDA: $8B

EV

$81B

Valuation Multiples

Multiples.vc

Start free trial

Takeda Pharmaceuticals Financials

Takeda Pharmaceuticals reported last 12-month revenue of $29B and EBITDA of $8B.

In the same LTM period, Takeda Pharmaceuticals generated $20B in gross profit, $8B in EBITDA, and $1B in net income.

Takeda Pharmaceuticals P&L

In the most recent fiscal year, Takeda Pharmaceuticals reported revenue of $32B and EBITDA of $8B.

Takeda Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Takeda Pharmaceuticals Stock Performance

Takeda Pharmaceuticals has current market cap of $55B, and enterprise value of $81B.

Takeda Pharmaceuticals' stock price is $35.09.

Takeda Pharmaceuticals Valuation Multiples

Takeda Pharmaceuticals trades at 2.8x EV/Revenue multiple, and 10.4x EV/EBITDA.

Takeda Pharmaceuticals Financial Valuation Multiples

As of April 18, 2026, Takeda Pharmaceuticals has market cap of $55B and EV of $81B.

Equity research analysts estimate Takeda Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Takeda Pharmaceuticals has a P/E ratio of 48.7x.

Takeda Pharmaceuticals Margins & Growth Rates

Takeda Pharmaceuticals' revenue in the last 12 month grew by 1%.

Takeda Pharmaceuticals' revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.

Takeda Pharmaceuticals' rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Takeda Pharmaceuticals' rule of X is 29% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Takeda Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Takeda Pharmaceuticals M&A Activity

Takeda Pharmaceuticals acquired XXX companies to date.

Last acquisition by Takeda Pharmaceuticals was on XXXXXXXX, XXXXX. Takeda Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Takeda Pharmaceuticals Investment Activity

Takeda Pharmaceuticals invested in XXX companies to date.

Takeda Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Takeda Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).